A Volumetric Absorptive Microsampling Technique to Monitor Cannabidiol Levels in Epilepsy Patients
Dubois et al.
The finding, in our words
Capillary blood collected by VAMS gave cannabidiol concentrations that agreed strongly with venous plasma (R² 0.93) in five paediatric and young adult patients with Dravet syndrome. This validates VAMS as a less invasive method for therapeutic drug monitoring of cannabidiol, enabling personalised therapy in refractory epilepsy within decentralised settings.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In children with SLE, VAMS finger-prick capillary blood gave haematocrit-adjusted MPA and MPAG concentrations indistinguishable from plasma, and the AUC from VAMS derived plasma-equivalent concentrations matched plasma AUC with R2 0.97. This supports accurate pharmacokinetically guided dosing of MMF using only three timed capillary microsamples.
Zhao et al., The journal of applied laboratory medicine (paywalled) · source ↗
The study validated a VAMS-based LC-MS/MS method for measuring sirolimus levels, showing it was clinically equivalent to the standard whole blood method and suitable for therapeutic drug monitoring in paediatric transplant patients, supporting the use of decentralised microsampling for this purpose.
Kocur et al., Pharmacological reports : PR · source ↗
A study of 50 paediatric renal transplant recipients found that a validated VAMS LC-MS/MS method for tacrolimus showed high correlation with the reference method over 0.5–60 ng/mL, with minimal haematocrit effect.
VAMS microsampling found no significant difference from venous blood for tacrolimus in paediatric patients; samples were stable for 14 days, with average difference between paired at-home samples of 0.12 ± 0.94 ng/mL.
Zhao et al., J. Mass Spectrometry and Advances in the Clinical Lab · source ↗
A study of 50 paediatric renal transplant recipients found that a UHPLC-MS/MS method successfully quantified mycophenolic acid in VAMS microsampling samples over a 0.10-15 µg/mL range. However, converting microsampling results to plasma equivalents using haematocrit-based regression is required for clinical interpretation, supporting patient-centric decentralised monitoring.
Kocur et al., Pharmacological reports : PR · source ↗